Actuate Therapeutics Inc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACTU research report →
Companyactuatetherapeutics.com
Actuate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
- CEO
- Daniel Schmitt
- IPO
- 2024
- Employees
- 10
- HQ
- Fort Worth, TX, US
Price Chart
Valuation
- Market Cap
- $60.05M
- P/E
- -2.74
- P/S
- 0.00
- P/B
- 15.61
- EV/EBITDA
- -2.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -430.93%
- ROIC
- -521.19%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-22,227,852 · 18.54%
- EPS
- $-1.06 · 67.48%
- Op Income
- $-22,495,312
- FCF YoY
- 12.07%
Performance & Tape
- 52W High
- $11.99
- 52W Low
- $1.58
- 50D MA
- $2.55
- 200D MA
- $5.47
- Beta
- 0.93
- Avg Volume
- 139.95K
Get TickerSpark's AI analysis on ACTU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Huber Martin H. Jr. | other | 30,000 |
| Apr 1, 26 | SCHMITT DANIEL M | other | 237,000 |
| Apr 1, 26 | Mazar Andrew Paul | other | 105,000 |
| Apr 1, 26 | LYTLE PAUL J | other | 105,000 |
| Feb 13, 26 | SCHMITT DANIEL M | other | 272,055 |
| Feb 13, 26 | SCHMITT DANIEL M | other | 272,055 |
| Feb 13, 26 | SCHMITT DANIEL M | other | 121,874 |
| Jan 5, 26 | THOMSON TODD S | sell | 280,000 |
| Jun 27, 25 | Bios Equity COF, LP | buy | 71,428 |
| Jun 27, 25 | Bios Equity COF, LP | buy | 71,428 |
Our ACTU Coverage
We haven't published any research on ACTU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACTU Report →